High-dose cyclophosphamide, etoposide and carboplatin with autologous bone marrow support for metastatic breast cancer: Long-term results

Bone Marrow Transplantation

Volumn 21, Issue 8, 1998, Pages 775-778

  Baker, W J ^a,c   Vukelja, S J ^a   Lee, N ^b   Perry, J J ^b  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Autologous bone marrow transplantation; High dose chemotherapy; Metastatic breast cancer

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLEEDING; BONE METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HUMAN; LIVER METASTASIS; LIVER TOXICITY; LUNG METASTASIS; LUNG TOXICITY; LYMPH NODE METASTASIS; METASTASIS; MUCOSA INFLAMMATION; PRIORITY JOURNAL; SEPSIS; THORAX WALL CANCER;

EID: 0031953320     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701173     Document Type: Article

References (13)

1. Eder J, Antman K, Peters W et al. High-dose combination alkylating agent chemotherapy with autologous marrow support for metastatic breast cancer. J Clin Oncol 1986; 4: 1592-1597.
2. Peters W, Shpall E, Jones R et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6: 1368-1376.
3. Antman K, Ayash L, Elias A et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in patients with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102-110.
4. Williams S, Gilewski T, Mich R, Bitran J. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. Follow-up report. J Clin Oncol 1992; 10: 1743-1747.
5. Greenberg P, Hortobaygi G, Smith T et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197-2205.
6. Decker D, Ahmann D, Bisel H. Complete responders to chemotherapy in metastatic breast cancer. JAMA 1979; 242: 2075-2079.
7. Dunphy F, Spitzer G, Fornoff J et al. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer 1994; 73: 2157-2167.
8. Ayash L, Wheeler C, Fairclough D et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem cell support for advanced breast cancer. J Clin Oncol 1995; 13: 2043-2049.
9. Dunphy F, Spitzer G, Buzdar A et al. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 1990; 8: 1207-1216.
10. Crown J, Kritz A, Vahdat L et al. Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer. J Clin Oncol 1993; 11: 1144-1149.
11. Ayash L, Elias A, Schwartz G et al. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. J Clin Oncol 1996; 14: 2984-2992.
12. Bezwoda W, Seymour L, Dansey R. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483-2489.
13. Jones R, Vredenburgh J, Shpall E et al. A large, prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Proc Am Soc Clin Oncol 1996; 15: 121.